Analysts Raise Targets on Affymetrix's Stock but Remain Cautious | GenomeWeb

NEW YORK (GenomeWeb News) – Analysts today upped their price targets on Affymetrix's stock, after the firm posted revenues and net income that surpassed analysts' consensus estimate.

After the close of the market yesterday, Affy reported total second-quarter revenue of $81.6 million, compared to $86.9 million in the comparable period of 2008. Though the revenues declined year over year, the results easily beat analysts' consensus estimates on both the top and bottom lines.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.